More Clinical Articles


Bayer Enters $540 Million Cancer Deal With Compugen

Lucy Brake, (Aug 6, 2013)

Bayer and Compugen have announced this week that they have signed a cancer immunotherapy deal which has the potential to be worth over US $540 million to the Israeli biotechnology company.

Drug Firms Praise New “Breakthrough” FDA Pathway

Ben Steele, (Jul 26, 2013)

Johnson & Johnson and Vertex Pharmaceuticals, two companies whose drugs have received “breakthrough therapy” designation, have spoken out in support of the FDA’s new breakthrough program, which could shave years off of the approval process.
Access and Evidence

UPDATED Exclusive: The Devil is in the Detail – How The Guardian's Bias Towards One Leaked Memo Proves Greater Transparency is Needed From All

Craig Sharp, (Jul 26, 2013)

The ongoing battle for clinical trial transparency took an unexpected turn this past Sunday, 21st July, when the Guardian ran a story featuring details of a leaked memo, apparently containing a plan to conceal “secret documents on drugs trials” from the public and concerned medical practitioners.
Access and Evidence

Exclusive: Richard Bergström Explains Transatlantic Joint Principles for Clinical Data Sharing

Craig Sharp, (Jul 26, 2013)

This week the European Federation of Pharmaceutical Industries and Associations (EFPIA) and Pharmaceutical Research and Manufacturers of America (PhRMA) released a joint position paper for responsible clinical trial data sharing to benefit patients.

The Pharma Potential to Tap into Biobanks

Lina Genovesi, (Jul 25, 2013)

George Dagher, PhD, coordinator of the French infrastructure for biobanks and leader of funding and financing WP, Biobanking and Biomolecular Resources Research Infrastructure (BBMRI) shares some thoughts with Lina Genovesi on the opportunities of biobanks for pharma.

Pay-for-Delay Deals could be Essential for More Generics and Cheaper Medicines

Anonymous, (Jul 24, 2013)

Limiting pay-for-delay deals will reduce pharmaceutical investment in generics and increase the cost of medicines for patients, states global economic consulting firm.

On Target – New Research Improves Drug Targeting

Lucy Brake, (Jul 23, 2013)

Scientists have developed a novel technique to provide more precise information about whether a drug has hit its target, ultimately making the drug development cycle less costly and more efficient.

Realizing the Potential of Stratified Medicines

Lucy Brake, (Jul 22, 2013)

A recent report from The Academy of Medical Sciences makes recommendations to address barriers to the widespread development and adoption of stratified medicine in the UK, in areas such as clinical development and pricing and reimbursement.

Research Develops Novel Drug Delivery System

Lucy Brake, (Jul 17, 2013)

Scientists at The University of Melbourne have developed an efficient system where tiny objects, such as bacterial cells, are coated with thin film membranes that assemble themselves.

More Approvals for Neglected Diseases but not R&D

Anonymous, (Jul 15, 2013)

Annual R&D spending for neglected diseases has been static since 2007 even though new research suggests that yearly approvals in this illness area have doubled in recent years.